Research programme: serotonin 6 receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: serotonin 6 receptor antagonists - GlaxoSmithKline

Alternative Names: 699929; GSK215083A; SB 357134; SB 699929

Latest Information Update: 18 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Piperazines; Sulfonamides
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 11 Sep 2008 Preclinical development is ongoing in United Kingdom
  • 13 Sep 2004 A preclinical study has been added to the Alzheimer's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top